2025 Q3 -tulosraportti
Vain PDF
79 päivää sitten
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
40 000
Myynti
Määrä
66 338
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 000 | SHB | NRD | ||
| 628 | AVA | NON |
Ylin
0,318VWAP
Alin
0,315VaihtoMäärä
0 4 628
VWAP
Ylin
0,318Alin
0,315VaihtoMäärä
0 4 628
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 18.11.2025 | |
| 2025 Q2 -tulosraportti | 29.8.2025 | |
| 2025 Q1 -tulosraportti | 20.5.2025 | |
| 2024 Q4 -tulosraportti | 28.2.2025 | |
| 2024 Q3 -tulosraportti | 18.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·29.1.So there is good news which I interpret as progress and very positive. https://www.linkedin.com/posts/monivent_monivent-neonatology-activity-7422640814150815746-c-5m?utm_source=share&utm_medium=member_ios&rcm=ACoAAEcs4eMBJoVUYazg2avgusLt-Hqu6EkvxFw- ·23.1.Really great work by the management and the team on the way to launch. The products are there now, a bit more liquidity needs to be found to execute for the rest of 2026. Just look at all the long-term owners, they are holding on and know that Monivent are the ONLY ones currently to take the market in EU and USA. One must remember it is a market of several Billion SEK to save the small lives. A bit more capital is needed, so some get cold feet and sell out, but here is an exciting case. I see a good acquisition opportunity and am not nervous about an increase in share capital or new investors at this level, I believe in huge upside market potential considering.
·22.12.2025This is a fantastic product that could be as groundbreaking as when the Anne doll and the standard pocket mask came out. It is extremely difficult to ventilate premature infants and newborns correctly. With such monitoring and feedback as this product provides, there are great opportunities to save lives and simplify correct ventilation. Dräger is big in blood gas within healthcare enterprises. So, a collaboration with them would carry significant weight. But then the question is whether they will invest together or if they will aim to acquire a potential bankruptcy estate and the patent. FDA approval is very critical for selling in the USA, where much revolves around documentation. I hope news comes soon that can point towards FDA approval, and then Dräger will be able to roll out this fantastic product at a high pace. Should also look at a similar solution for adults, as ventilation is difficult to perform correctly. Should be part of somewhat advanced first aid to achieve correct ventilation. (Breaths)!·22.12.2025 · MuokattuIt is a fantastic product with a greater purpose. We are close, and my guess is that the FDA has the case. This follows what appears to be a really good preliminary study. (I just found this online after intense searching) https://www.sciencedirect.com/science/article/pii/S2666520425002693?via%3Dihub I don't know if you are new to this stock, but I don't think we have a bankruptcy here. We have 2 crucial patents and a super super super product that, precisely because of patents, could potentially achieve a unique and dominant position. We also have a super skilled, passionate CEO here, a strong team, a truly skilled and competent chairman of the board, and regarding your mention of bankruptcy - the largest shareholder with just under 20% who knows what he's doing. And who has shown great commitment with a loan here at the finish line. Likewise, other leading figures backed it up. So again, no bankruptcy here in my clear conviction. Yes, we are hopefully right at the finish line after several capital increases. Drraeger is a super partner, and if they are not a partner in distribution and sales, they will buy the whole shop, but why sell if you are ready to operate.. That is my analysis. Good luck.
23.1.23.1.Tämä julkaisu on poistettu.·29.1.2025This from their Teaser: Subscription and guarantee commitments: The Company has received guarantee commitments in the form of a bottom guarantee of a total of SEK 1.65 million, corresponding to approximately 13 percent of the Rights Issue, and a top guarantee of a total of approximately SEK 5.2 million, corresponding to approximately 40 percent of the Rights Issue. Furthermore, subscription commitments have been submitted for a total of SEK 0.3 million. No remuneration is paid for the subscription commitments. Compensation for guarantee commitments is paid with 20 percent of the guaranteed amount in the form of newly issued shares in the Company. The Rights Issue is thus covered by guarantee and subscription commitments amounting to approximately 55 percent of the Rights Issue. Conversion of the bridge loan raised on October 9, 2024 including interest constitutes approximately 45% of the rights issue, which means that the rights issue is 100% covered by entered into commitments and is thus considered 100% secured.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
79 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·29.1.So there is good news which I interpret as progress and very positive. https://www.linkedin.com/posts/monivent_monivent-neonatology-activity-7422640814150815746-c-5m?utm_source=share&utm_medium=member_ios&rcm=ACoAAEcs4eMBJoVUYazg2avgusLt-Hqu6EkvxFw
- ·23.1.Really great work by the management and the team on the way to launch. The products are there now, a bit more liquidity needs to be found to execute for the rest of 2026. Just look at all the long-term owners, they are holding on and know that Monivent are the ONLY ones currently to take the market in EU and USA. One must remember it is a market of several Billion SEK to save the small lives. A bit more capital is needed, so some get cold feet and sell out, but here is an exciting case. I see a good acquisition opportunity and am not nervous about an increase in share capital or new investors at this level, I believe in huge upside market potential considering.
- ·22.12.2025This is a fantastic product that could be as groundbreaking as when the Anne doll and the standard pocket mask came out. It is extremely difficult to ventilate premature infants and newborns correctly. With such monitoring and feedback as this product provides, there are great opportunities to save lives and simplify correct ventilation. Dräger is big in blood gas within healthcare enterprises. So, a collaboration with them would carry significant weight. But then the question is whether they will invest together or if they will aim to acquire a potential bankruptcy estate and the patent. FDA approval is very critical for selling in the USA, where much revolves around documentation. I hope news comes soon that can point towards FDA approval, and then Dräger will be able to roll out this fantastic product at a high pace. Should also look at a similar solution for adults, as ventilation is difficult to perform correctly. Should be part of somewhat advanced first aid to achieve correct ventilation. (Breaths)!·22.12.2025 · MuokattuIt is a fantastic product with a greater purpose. We are close, and my guess is that the FDA has the case. This follows what appears to be a really good preliminary study. (I just found this online after intense searching) https://www.sciencedirect.com/science/article/pii/S2666520425002693?via%3Dihub I don't know if you are new to this stock, but I don't think we have a bankruptcy here. We have 2 crucial patents and a super super super product that, precisely because of patents, could potentially achieve a unique and dominant position. We also have a super skilled, passionate CEO here, a strong team, a truly skilled and competent chairman of the board, and regarding your mention of bankruptcy - the largest shareholder with just under 20% who knows what he's doing. And who has shown great commitment with a loan here at the finish line. Likewise, other leading figures backed it up. So again, no bankruptcy here in my clear conviction. Yes, we are hopefully right at the finish line after several capital increases. Drraeger is a super partner, and if they are not a partner in distribution and sales, they will buy the whole shop, but why sell if you are ready to operate.. That is my analysis. Good luck.
- 23.1.23.1.Tämä julkaisu on poistettu.·29.1.2025This from their Teaser: Subscription and guarantee commitments: The Company has received guarantee commitments in the form of a bottom guarantee of a total of SEK 1.65 million, corresponding to approximately 13 percent of the Rights Issue, and a top guarantee of a total of approximately SEK 5.2 million, corresponding to approximately 40 percent of the Rights Issue. Furthermore, subscription commitments have been submitted for a total of SEK 0.3 million. No remuneration is paid for the subscription commitments. Compensation for guarantee commitments is paid with 20 percent of the guaranteed amount in the form of newly issued shares in the Company. The Rights Issue is thus covered by guarantee and subscription commitments amounting to approximately 55 percent of the Rights Issue. Conversion of the bridge loan raised on October 9, 2024 including interest constitutes approximately 45% of the rights issue, which means that the rights issue is 100% covered by entered into commitments and is thus considered 100% secured.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
40 000
Myynti
Määrä
66 338
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 000 | SHB | NRD | ||
| 628 | AVA | NON |
Ylin
0,318VWAP
Alin
0,315VaihtoMäärä
0 4 628
VWAP
Ylin
0,318Alin
0,315VaihtoMäärä
0 4 628
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 18.11.2025 | |
| 2025 Q2 -tulosraportti | 29.8.2025 | |
| 2025 Q1 -tulosraportti | 20.5.2025 | |
| 2024 Q4 -tulosraportti | 28.2.2025 | |
| 2024 Q3 -tulosraportti | 18.11.2024 |
2025 Q3 -tulosraportti
Vain PDF
79 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 18.11.2025 | |
| 2025 Q2 -tulosraportti | 29.8.2025 | |
| 2025 Q1 -tulosraportti | 20.5.2025 | |
| 2024 Q4 -tulosraportti | 28.2.2025 | |
| 2024 Q3 -tulosraportti | 18.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·29.1.So there is good news which I interpret as progress and very positive. https://www.linkedin.com/posts/monivent_monivent-neonatology-activity-7422640814150815746-c-5m?utm_source=share&utm_medium=member_ios&rcm=ACoAAEcs4eMBJoVUYazg2avgusLt-Hqu6EkvxFw
- ·23.1.Really great work by the management and the team on the way to launch. The products are there now, a bit more liquidity needs to be found to execute for the rest of 2026. Just look at all the long-term owners, they are holding on and know that Monivent are the ONLY ones currently to take the market in EU and USA. One must remember it is a market of several Billion SEK to save the small lives. A bit more capital is needed, so some get cold feet and sell out, but here is an exciting case. I see a good acquisition opportunity and am not nervous about an increase in share capital or new investors at this level, I believe in huge upside market potential considering.
- ·22.12.2025This is a fantastic product that could be as groundbreaking as when the Anne doll and the standard pocket mask came out. It is extremely difficult to ventilate premature infants and newborns correctly. With such monitoring and feedback as this product provides, there are great opportunities to save lives and simplify correct ventilation. Dräger is big in blood gas within healthcare enterprises. So, a collaboration with them would carry significant weight. But then the question is whether they will invest together or if they will aim to acquire a potential bankruptcy estate and the patent. FDA approval is very critical for selling in the USA, where much revolves around documentation. I hope news comes soon that can point towards FDA approval, and then Dräger will be able to roll out this fantastic product at a high pace. Should also look at a similar solution for adults, as ventilation is difficult to perform correctly. Should be part of somewhat advanced first aid to achieve correct ventilation. (Breaths)!·22.12.2025 · MuokattuIt is a fantastic product with a greater purpose. We are close, and my guess is that the FDA has the case. This follows what appears to be a really good preliminary study. (I just found this online after intense searching) https://www.sciencedirect.com/science/article/pii/S2666520425002693?via%3Dihub I don't know if you are new to this stock, but I don't think we have a bankruptcy here. We have 2 crucial patents and a super super super product that, precisely because of patents, could potentially achieve a unique and dominant position. We also have a super skilled, passionate CEO here, a strong team, a truly skilled and competent chairman of the board, and regarding your mention of bankruptcy - the largest shareholder with just under 20% who knows what he's doing. And who has shown great commitment with a loan here at the finish line. Likewise, other leading figures backed it up. So again, no bankruptcy here in my clear conviction. Yes, we are hopefully right at the finish line after several capital increases. Drraeger is a super partner, and if they are not a partner in distribution and sales, they will buy the whole shop, but why sell if you are ready to operate.. That is my analysis. Good luck.
- 23.1.23.1.Tämä julkaisu on poistettu.·29.1.2025This from their Teaser: Subscription and guarantee commitments: The Company has received guarantee commitments in the form of a bottom guarantee of a total of SEK 1.65 million, corresponding to approximately 13 percent of the Rights Issue, and a top guarantee of a total of approximately SEK 5.2 million, corresponding to approximately 40 percent of the Rights Issue. Furthermore, subscription commitments have been submitted for a total of SEK 0.3 million. No remuneration is paid for the subscription commitments. Compensation for guarantee commitments is paid with 20 percent of the guaranteed amount in the form of newly issued shares in the Company. The Rights Issue is thus covered by guarantee and subscription commitments amounting to approximately 55 percent of the Rights Issue. Conversion of the bridge loan raised on October 9, 2024 including interest constitutes approximately 45% of the rights issue, which means that the rights issue is 100% covered by entered into commitments and is thus considered 100% secured.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
40 000
Myynti
Määrä
66 338
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 000 | SHB | NRD | ||
| 628 | AVA | NON |
Ylin
0,318VWAP
Alin
0,315VaihtoMäärä
0 4 628
VWAP
Ylin
0,318Alin
0,315VaihtoMäärä
0 4 628
Välittäjätilasto
Dataa ei löytynyt